United States: Wilmerhale Represents Kala Pharmaceuticals In $103.5 Million IPO
Last Updated: August 14 2017

On July 25, 2017, Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of two Phase 3 product candidates, KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease using its proprietary mucus-penetrating particle (MPP) technology, announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters' exercise in full of their option to purchase an additional 900,000 shares, at the public offering price of $15.00 per share. The exercise of the underwriters' option brought the amount of gross proceeds raised in the offering to approximately $103.5 million, before underwriting discounts, commissions and estimated expenses of the offering.

The WilmerHale team representing Kala in the transaction was led by Lia Der Marderosian and included Ryan Mitteness, Emily Gainor, Alex Civetta and Heidi Treiber.

Kala's press release is available here.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
By WilmerHale
By Robert D. Burke, A. William Caporizzo, Julie Hogan Rodgers, Meghan Walsh
By WilmerHale
By Jamie Gorelick, William McLucas, Bruce M. Berman, Danielle Conley, Tania Faransso
Font Size: